Hepatitis C drugs face four patent challenges in India

India-based Initiative for Medicines, Access & Knowledge (I-MAK) has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

AbbVie faces hepatitis C patent challenge in India

26 July 2018 In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

AbbVie faces hepatitis C patent challenge in India

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

AbbVie faces hepatitis C patent challenge in India